Phase 2, B-Cell Maturation Antigens (BCMA) Bispecific Antibody, 3,>=4 prior line of therapy, Relapsed Refractory Multiple Myeloma (RRMM), Teclistamab
### Instruction:
Identify the study with the following condition. 
### Input:
Phase 2, B-Cell Maturation Antigens (BCMA) Bispecific Antibody, 3,>=4 prior line of therapy, Relapsed Refractory Multiple Myeloma (RRMM), Teclistamab 
### Output:
Popular Name is MajesTEC-1, Study ID is NCT04557098